Rahul Karnik

Computational biologist at @KymeraTx #computationalbiology #generegulation #chromatin #genomics #epigenetics

[Kymera Therapeutics @KymeraTx]

Today, we shared positive clinical data from our KT-474 Phase 1 hidradenitis suppurativa and atopic dermatitis patient cohort, as well as updates on our three oncology programs, KT-413, KT-333 and KT-253. For more information, please visit: https://t.co/ZM00lr3BJM

[Kymera Therapeutics @KymeraTx]

Save the date for our upcoming Investor Webcast, where we’ll share data from our KT-474 Phase I patient cohort and clinical #oncology trials.

Learn more:https://t.co/kjBlJgQchR #biotech #clinicaltrials #research

[Nina Beguš @ninabegus]

Ada Lovelace, the first programmer, begging her collaborator Charles Babbage, the inventor of the first general computer, not to mess with her math

[Rahul Karnik @genebrew]

Booked a trip for my in-laws on @Arangrant. When one leg was canceled, @TurkishAirlines said we have to go through Arangrant to rebook. We have had an open request with Arangrant for 7 days. Trip next weekend. Prices are competitive, but terrible customer service. Beware.

[Jamie Hackett @hackettlab]

📢Preprint drop! -Are chromatin modifications a cause or consequence of transcription? (or both)

How do DNA motifs affect the function of marks? Can combinatorial modifications synergise?

We present our epigenome editing study, & unexpected findings👇+🧵
https://t.co/Mrq6HWvgsh

[Nasdaq Exchange @NasdaqExchange]

Welcoming @KymeraTx to the @NasdaqExchange Opening Bell! https://t.co/3vPdQhwL6z

[Rahul Karnik @genebrew]

Right down your alley @andyratcliffe9

[Science girl @sciencegirl]

In the resort town of Les 2 Alpes, in the northern French Alps there is a bike race which starts at a 3,400m-high glacier. 1/2

[Rahul Karnik @genebrew]

@BioMickWatson If I didn’t follow you on Twitter, I would have thought you were talking about Perl.

[Kymera Therapeutics @KymeraTx]

How is @KymeraTX harnessing the power of #proteindegradation in #autoimmune diseases? Hear our Director of Immunology, Veronica Campbell, present on our protein degrader, IRAK4 and STAT3, and more: https://t.co/wR7CrsTub3

[Rahul Karnik @genebrew]

@lpachter Got it: https://t.co/GZ0U9nzg3o

[Rahul Karnik @genebrew]

@lpachter Paper link, please.

[Rahul Karnik @genebrew]

@MotherOfPhage Oh god, there goes my Friday evening trying to figure out the author.

[Kymera Therapeutics @KymeraTx]

@KymeraTx is thrilled to announce the first patients dosed in our Phase 1 trials for KT-333 and KT-413. Read more about how we’re pioneering precision cancer therapeutics at https://t.co/dPyviaY2ZY #Biotech #DrugDiscovery #ClinicalTrials #Oncology #Cancer

[Rahul Karnik @genebrew]

The War in Ukraine and the Rush to Feed the World | BCG https://t.co/IfoNszAYBG

[Kymera Therapeutics @KymeraTx]

IRAK4 degradation demonstrates potential superiority in treatment efficacy in comparison to kinase inhibition. Learn more about IRAK4 degradation’s potential to address a wide breadth of indications at https://t.co/TlD8bzVG4a
#biotech #drugdiscovery #AAI2022

[Kymera Therapeutics @KymeraTx]

Thrilled to hear @FastCompany has honored Kymera as a company “making a world-changing impact” for our first-in-class STAT3 Small Molecule Degrader, KT-333. Congratulations to the team working on this molecule. We’re proud of your hard work and dedication. https://t.co/QsLEWwTYPe

[Alexandra Mattei @AL_Mattei]

What does DNA methylation do again? Our answer in 32 short pages. Excited to finally get to share a true labor of love Nina Bailly and I worked on together throughout the pandemic, a swan song to my PhD and time in Germany. https://t.co/2PrbMim23e

[Rahul Karnik @genebrew]

@NasirBhanpuri @celtics @warriors @Suns @FiveThirtyEight @memgrizz @BetMGM If only fandom affected outcomes (I am a @sixers fan). How does your model handle injuries? For players with a history of injuries like Embiid or Chris Paul, those (predictable?) events seem to throw off the predictions a lot.

[Kymera Therapeutics @KymeraTx]

By utilizing our proprietary platform and tissue-identification criteria, @KymeraTx has identified a novel tissue-sparing E3 ligases with the potential for broad utility in solid tumor indications. Learn more at https://t.co/EtLG3zRzfI #biotech #drugdiscovery @Undruggable